Staying The Course: PhRMA Announces ‘Pro-Consumer’ Reform Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Recently installed CEO Stephen Ubl presents policy solutions as industry’s best response to ongoing public criticism over high drug prices.
You may also be interested in...
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn
Concern about disrupting the implementation of the negotiation program could presage a tough road for the legislation in the Democrat-controlled Senate.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.